Equities

Ascelia Pharma AB

Ascelia Pharma AB

Actions
  • Price (EUR)0.154
  • Today's Change-0.017 / -9.73%
  • Shares traded25.50k
  • 1 Year change-27.25%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments22150262
Total Receivables, Net2.464.535.56
Total Inventory------
Prepaid expenses4.626.797.45
Other current assets, total--0.00--
Total current assets29161275
Property, plant & equipment, net1.060.631.82
Goodwill, net------
Intangibles, net575757
Long term investments------
Note receivable - long term------
Other long term assets0.000.00--
Total assets87219333
LIABILITIES
Accounts payable1.53166.15
Accrued expenses8.522016
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.880.291.10
Other current liabilities, total1.641.691.51
Total current liabilities133825
Total long term debt0.180.190.55
Total debt1.060.481.66
Deferred income tax------
Minority interest------
Other liabilities, total--0.00--
Total liabilities133826
SHAREHOLDERS EQUITY
Common stock353535
Additional paid-in capital------
Retained earnings (accumulated deficit)(640)(533)(406)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total679679679
Total equity74181308
Total liabilities & shareholders' equity87219333
Total common shares outstanding504949
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.